Graphical Abstract Highlights d Intranasal T cell epitope-targeted vaccination confers enhanced protection d Intranasal vaccination preferentially induces CXCR3 LO lungresident memory CD8 + T cells d Protective memory T cells localize to vulnerable sites of the lung interstitium d Interstitial memory CD8 + T cells rapidly protect the lung against infection In Brief Mucosal surveillance ensures rapid protection when a pathogen breaches the barrier. Gilchuk et al. report that local vaccination elicits a distinct resident memory CD8 + T cell subset that localizes to the lung interstitium. These T cells protect against respiratory infections by positioning at vulnerable sites and acting quickly against infections.
INTRODUCTION
Memory of past encounters with pathogens is a key feature of the adaptive immune system and the basis for successful vaccination. Antigen-specific memory CD8 + T cells play key roles in protection against infectious diseases. A delay in the generation of effector CD8 + T cells and/or the recall of circulating memory CD8 + T cells to the site of infection allows pathogens to replicate and cause disease. Non-circulating tissue-resident memory CD8 + T (TRM) cells, by virtue of their optimal positioning at bar-riers (e.g., skin, intestine, female reproductive tract, and respiratory tract), keep infections in check at sites of pathogen entry to confer protective immunity (Ariotti et al., 2012; Bergsbaken and Bevan, 2015; Bivas-Benita et al., 2013; Hickman et al., 2015; Jiang et al., 2012; Li et al., 2013; Mackay et al., 2013; Salek-Ardakani et al., 2011; Sheridan et al., 2014; Shin and Iwasaki, 2012; Sl€ utter et al., 2013; Takamura et al., 2010) . Hence, insights into the generation and function of TRM cells are essential for devising ways to induce protective immunity by vaccination (Clark, 2015; .
The respiratory mucosa is a major site for pathogen invasion and, hence, a site for constant immune surveillance. Safeguarding the lungs (especially the terminal respiratory tree that consists of alveoli and associated capillary beds) from injury is critical to preserve lung function. Thus, severe morbidity and mortality in respiratory infectious diseases are associated with viral dissemination and inflammation, which can damage the lung parenchyma and alveoli (Gilchuk et al., 2013; Manicassamy et al., 2010) . To protect from disease, memory CD8 + T cells are strategically distributed within distinct anatomical compartments of the lungs (Hasenberg et al., 2013; Lelkes et al., 2014; Rangel-Moreno et al., 2011) . The anatomical niche that memory CD8 + T cells occupy in the lungs depends on the route of infection (Anderson et al., 2012) . Nonetheless, the precise location and protective capacity of different CD8 + TRM cell subsets in the lungs that are elicited by vaccination are poorly understood.
Most vaccines in clinical use, including those protecting against respiratory infections, are administrated to elicit systemic rather than local immune responses. Live and attenuated microbes are dangerous for use as pulmonary vaccines, and inactivated microbes poorly elicit cellular immunity. Consequently, there is a need for physiologically relevant experimental models that closely recapitulate protective CD8 + TRM cell responses to vaccination in the lungs. Here, we describe a model in which lower airway vaccination with a non-replicative pathogenderived protein antigen elicits high frequency of epitope-specific CD8 + TRM cells within the lung tissue that conferred rapid protection to mice against lethal vaccinia virus (VACV) infection of the lower respiratory tract. A comparative analysis of the outcomes of distinct vaccination routes revealed that the protective CD8 + TRM cell subset localized to a spatially distinct niche within the lung parenchyma and exhibited unique phenotypic features.
RESULTS

Intranasal Vaccination with Antigenic Protein Plus Adjuvant Confers Enhanced Protection against Respiratory Virus Infection
We previously reported two HLA-B7.2-restricted VACV-derived CD8 + T cell epitopes: B8R 70-78 (B8R), which elicited a protective polyclonal CD8 + T cell response upon peptide vaccination; and L4R 37-45 , which elicited a robust CD8 + T cell response but was non-protective for reasons previously reported (Gilchuk et al., 2013) . This finding was exploited to dissect the protective capabilities of endogenous (non-T cell receptor [TCR] transgenic), epitope-specific CD8 + T cells. We engineered two recombinant (C) Frequency of epitope-specific CD8 + T cells was enumerated on day 6 after boost in blood using the corresponding tetramers. Each symbol indicates an individual mouse.
(D) Protection of mice that were IP vaccinated with aGC-formulated L4R or L4R-b8r protein antigens.
(E) Protection of mice that were IP or intranasally vaccinated with L4R-b8r plus aGC.
(F) VACV burden in the lungs was measured on days 2, 4, and 6 p.i. in mice vaccinated as in (E); n = 5-21 mice/group, mean ± SEM; number indicates percent survival based on endpoint criteria. See also Figure S1 .
VACV-derived proteins (L4R and L4R-b8r). To create L4R-b8r, the native nonprotective L4R 37-45 peptide in L4R was substituted with the protective B8R epitope. Thus, L4R and L4R-b8r are made of the same protein scaffold but differ only in the epitope they contain ( Figure 1A) .
To test the immunogenicity of L4R and L4R-b8r, HLA-B7.2 transgenic (B7.2 tg ) mice were primed and boosted intraperitoneally (IP) ( Figure 1B ) with the protein antigen formulated with a-galactosylceramide (aGC) as the adjuvant (Gilchuk et al., 2013; Semmling et al., 2010) . Staining with the corresponding B7.2-peptide tetramer (Tet) showed that both protein antigens induced a robust systemic CD8 + T cell response ( Figure 1C ). The response was specific to the epitope used for immunization, because the elicited CD8 + T cells reacted only with the cognate tetramer ( Figure S1 ). Moreover, under conditions promoting severe lower airway infection, intraperitoneal vaccination with L4R-b8r was sufficient to protect mice from a lethal respiratory VACV challenge, while L4R-vaccinated mice succumbed to disease ( Figure 1D ). Thus, B8R-specific CD8 + T cells were the sole mediators of protection, with undetectable contribution by other adaptive immune cells to the antigen or the adjuvant. We next compared the protective potential of memory B8R-specific CD8 + T cells generated by intraperitoneal and intranasal (IN) vaccinations. Strikingly, intranasally vaccinated mice lethally challenged with VACV were more resistant to disease and showed lower VACV titers in the lung as early as day 1 post-infection (p.i.) ( Figures 1E and 1F ). We concluded that IN vaccination, when compared to intraperitoneal vaccination, with CD8 + T cell-targeted antigen more efficiently protected mice from lethal respiratory VACV infection.
Epitope-Specific CD8 + T Cells Elicited by Protein
Vaccination Mediate Long-Term Protection against Lethal Virus Infection IN aGC administration rapidly induces local inflammatory responses and interferon-g (IFN-g) production (Courtney et al., 2011) , potentially explaining the enhanced protection observed when aGC was used as an adjuvant. To investigate antigen specificity of the observed protective immune responses, we primed and boosted mice intranasally with aGC alone or with aGC plus L4R-b8r and then challenged them with VACV on day 14 or on day 24 after boost. We chose day 24 after boost because aGCinduced IFN-g responses in the lungs wane substantially by then (Courtney et al., 2011) . We found that IN aGC treatment 14 days before challenge played very little role in conferring protective immunity that waned after 3 weeks. (Figures 2A, 2B , S2A, and S2B). Thus, B8R-specific CD8 + T cells in the lungs participate in enhanced protection to respiratory infection.
To directly demonstrate that CD8 + T cells elicited upon IN vaccination participated in protection, we locally depleted them by IN aCD8 antibody (Ab) delivery (Sl€ utter et al., 2013) . Lung TRM cells were quantified after intravascular (IV) staining with aCD45 Ab in vivo to identify circulating blood leucocytes (Anderson et al., 2014) . Local CD8 + T cell depletion significantly decreased the number of CD8 + TRM cells in the lungs (Tet + aCD45 Ab À ) but maintained intravascular CD8 + T cells (Tet + (C) Protection of intranasally vaccinated mice that received 5 mg aCD8 Ab or PBS (mock) intranasally and challenged 48 hr later with a lethal dose of VACV. TRM cells were assessed in the lungs of both groups at 24 hr after the treatment using IV staining. (D) Protection of mice that were vaccinated intranasally with L4R-b8R plus aGC and challenged with VACV on day 50 after boost. Data are pooled from two or more independent experiments using n = 3 or more mice/group (A and B). One of two independent experiments for (C) and (D), n = 3-14 mice/group; mean ± SEM. Finally, we investigated the duration of protection by memory CD8 + T cells elicited after intraperitoneal or IN vaccination. Notably, only intranasally vaccinated and not IP-vaccinated mice were protected when challenged intranasally with VACV at day 50 after boost, suggesting a key role for IN vaccination in establishing long-lasting protective immunity ( Figure 2D ). These data together established a non-TCR transgenic mouse model to study the basis of immune protection rendered against lethal respiratory infection by endogenous lung CD8 + TRM cells.
Intranasal Vaccination Elicits a Distinct CXCR3 LO CD8 + TRM Cell Subset in the Lung Interstitium
We next investigated the immunologic properties of B8R-specific CD8 + T cells elicited by intraperitoneal or IN vaccination. We found that both immunization routes elicited robust systemic and local pulmonary memory CD8 + T cell responses of comparable frequency ( Figure 3A ). B8R-specific CD8 + T cells elicited by both vaccination routes responded to antigen by producing IFN-g and mobilizing CD107a to the cell surface (Figures S3A and S3B) . Upon IN VACV challenge, a higher frequency of responding B8R-specific CD8 + T cells was found in the lungs of IP-vaccinated mice when compared to those of intranasally vaccinated mice ( Figures S3C and S3D ). Hence, the frequency of antigen-specific CD8 + T cells capable of producing IFN-g and degranulate fail to explain why IN vaccination enhances protective immunity.
The airways and the lung parenchyma are composed of specialized immunological niches (Hasenberg et al., 2013) suggesting that local versus systemic vaccination results in differential localization of memory CD8 + T cells within the lungs. By staining with aCD45 Ab in vivo and with aCD8 Ab and Tet ex vivo, the distribution of airway (AW)-resident CD8 + T cells in bronchoalveolar lavage (BAL) and parenchymal CD8 + T cells in two anatomically distinct compartments of the lungs (the vasculature [''marginated'' vascular (MV)] and interstitium [interstitial (IST)]) were assessed in response to the two immunization routes. We found that the Tet + aCD45 Ab À CD8 + T cells of the BAL and lung parenchyma were attributed to AW and IST TRM cells, respectively ( Figure 3B ), as previously suggested by others (Anderson et al., 2014; Barletta et al., 2012) .
Most B8R-specific CD8 + T cells (>95%), after intraperitoneal immunization but prior to challenge were Tet + aCD45 Ab + representing the MV memory pool confined to the lung vasculature ( Figures 3B and 3C) . In contrast, after IN immunization, B8R-spe- cific CD8 + T cells were located within the lung interstitium (Tet + aCD45 Ab À ), vasculature (Tet + aCD45 Ab + ), and airways (Tet + aCD45 Ab À ). Remarkably, IST TRM cells comprised a large fraction (>50%) and AW TRM cells represented only a minor fraction (<2%) of total memory CD8 + T cells in the lungs (Figures 3B and 3C) . Thus, local antigen exposure and inflammation are critical for generating and maintaining a high frequency of IST TRM cells in the lungs.
The frequency of MV and IST CD8 + T cells in perfused lungs was >3-to 10fold higher than in the blood or lung-associated lymph nodes (LNs) ( Figures S4A  and S4B ). Hence, the MV and IST memory CD8 + T cells detected in this study were confined to lung parenchyma and were not blood or LN contaminants. Tet + aCD45 Ab À TRM cells recovered from the BAL uniformly expressed CXCR3 HI , a marker for AW TRM cells (Kohlmeier et al., 2009; Sl€ utter et al., 2013) . In contrast, Tet + aCD45 Ab À TRM cells retained in the lung parenchyma after perfusion were CXCR3 LO , suggesting no cross-contamination between AW and IST TRM cells ( Figure S4C ).
Resting IST TRM cells were composed of CD103 HI and CD103 LO/NEG subsets that expressed higher levels of CD69 and CD44 than MV CD8 + T cells and were KLRG1 LO , CD62L LO , CCR7 LO , CD122 LO , and CD127 HI , a phenotype consistent with the current definition of a TRM cell ( Figure 3D ). Unlike CXCR3 HI AW TRM cells, IST TRM cells were CXCR3 LO , thereby discriminating between the two TRM cell subsets in the lungs ( Figures  3D and S4C ). Resting and activated IST TRM cells were responsive to re-stimulation with antigenic peptide and stained for GzmB ex vivo ( Figure 3D ; data not shown). Thus, IN immunization with a non-replicative immunogen and aGC elicited functionally competent and CXCR3 LO memory CD8 + T cells that occupied a distinct anatomical niche in immune lungs and acquired a tissue resident phenotype.
IST TRM Cells Persist in the Lungs and Respond before Systemic Memory CD8 + T Cells Are Recruited to the Site of Infection We next determined the prevalence of B8R-specific CD8 + T cells within the lung parenchyma and BAL after intraperitoneal or IN vaccination and during infection ( Figure 4A ). Regardless of the vaccination route, similar numbers of MV Tet + CD8 + T cells were detected in the lungs at day 14 post-boost and until day 4 after lethal IN VACV challenge. Strikingly, at the same time points there were $15to 40-fold higher numbers of IST TRM cells in intranasally vaccinated lungs as compared to IP-immunized lungs ( Figure 4A ). Moreover, IN vaccination established $3 3 10 4 IST TRM cells per lung, which accounted for >98% of total lung CD8 + TRM cells during early infection. This IST TRM cell number is likely an underestimate, owing to dramatic cell losses (>98%) incurred during tissue processing (Steinert et al., 2015) . IN immunization also induced $500 AW CD8 + TRM cells per lung, which were undetectable in IP-immunized mouse lungs ( Figure 4A ). This small population of AW TRM cells was sustained in the airways without substantial change in number until day 6 p.i. The dramatically higher number of pre-existing IST TRM cells present during early infection was associated with the rapid reduction of viral load in intranasally vaccinated mice. Conversely, the delayed accumulation of IP-induced memory CD8 + T cells in the lung tissue was consistent with the increased VACV burden in these mice ( Figure 1F ).
Efficient CD8 + T cell-mediated immune surveillance in infected tissues requires a high density of responders (Halle et al., 2016) , with an estimate of $3,000 TRM cells per million nucleated cells in the lungs (Steinert et al., 2015) . Hence, we hypothesized that the highly abundant IST TRM cells, in comparison to $500 AW TRM cells, participated in the rapid control of the infection established with $10 5 PFU VACV that spreads through $2 3 10 6 alveoli. To test this hypothesis, we attempted adoptive transfer or selective local depletion of AW or IST TRM cells before VACV challenge. We could not repopulate the lungs with a physiological density of endogenous epitope-specific IST TRM cells because of poor yields (Steinert et al., 2015) and poor homing efficiency (data not shown). IN application of aCD8 Ab depleted AW TRM cells as expected (Sl€ utter et al., 2013) , but significantly reduced IST TRM as well ( Figures S2C-S2E ). As an alternative approach, we repopulated the airways of IP-vaccinated mice with $770 B8Rspecific AW TRM cells per lung, which approximates two times their physiological number, harvested from intranasally vaccinated and VACV-challenged mice. The transferred AW TRM cells neither egressed into the lung parenchyma nor provided resistance to VACV infection ( Figure S5 ). Together these data suggest that IST TRM cells elicited by IN, but not intraperitoneal, vaccination conferred early virus control and enhanced protection.
To determine why the pre-existing systemic memory CD8 + T cells accumulated slowly in the infected lungs, we assessed their proliferation kinetics. For this, IP-vaccinated mice were intranasally challenged with VACV and then pulsed with EdU (5-ethynyl-2 0 -deoxyuridine) for 1 day. B8R-specific AW and IST TRM cells showed modest EdU incorporation by day 4 p.i. and profound incorporation by day 6 p.i. By contrast, proliferation of B8R-specific blood, splenic, and lung MV CD8 + T cells was obvious only by day 6 p.i. (Figure 4B ). Although it is likely that memory CD8 + T cells were proliferating in the draining LN at this time point (Moyron-Quiroz et al., 2006) , proliferating cells were not detected in the blood and spleen until day 6 p.i. This result suggested that systemic CD8 + T cells had not yet left the LN to participate in viral clearance. The increased total number of B8R-specific IST TRM cells in the lungs observed on day 4 p.i. was inversely related to $3to 8-fold lower B8R-specific CD8 + T cells in blood, spleen, and lung vasculature ( Figure 4C) . Thus, the delayed recruitment of systemic resting memory CD8 + T cells to the lungs accounted for late accumulation of IST and AW TRM cells during infection, which then extensively proliferated in situ.
By virtue of their location, IST TRM cells can quickly engage in contact-dependent killing of infected lung tissue to confer enhanced immune protection, whereas MV CD8 + T cells are spatially isolated and cannot do so. To assess early activation of CD8 + T cell subsets in the lungs, intranasally immunized mice were challenged with VACV, and B8R epitope-specific MV CD8 + T cells (mostly CD69 LO ) and IST TRM (mostly CD69 HI ) were assessed for CD69 induction within 36 hr p.i. Remarkably, only IST TRM cells and not MV CD8 + T cells upregulated CD69 expression ( Figure 4D ), suggesting that IST TRM cells are key initial responders to infection.
Interstitial TRM Localize to Sites of the Lungs that Are Vulnerable to Infection
We previously showed that mortality in naive VACV-challenged mice was due to severe damage of alveoli characterized by widespread necrosis and fibrin-filled and edematous alveolar spaces (Gilchuk et al., 2013) . Here, we determined the sites of VACV infection following IN inoculation with GFP reporter virus (Norbury et al., 2002) in conjunction with fluorescent labeling of type I alveolar epithelial cells with anti-rodoplanin Ab (Vanderbilt et al., 2008) on day 4 p.i. Confocal microscopy revealed that VACV localized to two spatially distinct niches surrounding the bronchioles and type I epithelial cells that form the alveolar walls ( Figure 5A ). Accordingly, imaging of aCD45 Ab À CD8 + T cells in acutely infected lungs of vaccinated mice showed localization to the sites that are vulnerable to VACV infection, including the bronchioles and alveolar walls ( Figure 5B ).
Imaging of endogenous antigen-specific CD8 + T cells in the lungs was reported previously (Khanna et al., 2008; Moyron-Quiroz et al., 2006) , but whether CD8 + TRM cells occupy niches in the lung parenchyma where fatal infection occurs remains unknown. The pulmonary interstitium is the support tissue within the lungs; it includes the alveolar epithelium, capillary bed endothelium, basement membrane, and the perivascular and perilymphatic tissues. Collectively, they constitute the walls of the bronchioles and alveoli. To determine the location of VACV-specific IST TRM cells, we stained thick fresh lung sections with fluorescent B8R tetramer (red) after IV labeling of vascular leucocytes with aCD45 Ab (blue) and vascular endothelium of alveolar capillary beds with fluorescent tomato lectin (green (legend continued on next page) plane illumination microscopy (SPIM), we achieved volumetric imaging that allowed visualization of VACV-specific CD8 + T cells in the alveolar interstitium (IST TRM, red) and alveolar capillary beds (MV CD8 + T cells, magenta from the merge of red and blue) (see Figure 5C ). We found that IN vaccination induced a substantial number of IST TRM cells that localized within the alveolar walls, outside of alveolar capillaries ( Figure 5C ). Such a location of IST TRM cells was even more prominent in acutely infected lungs of intranasally vaccinated mice, showing that infected alveoli are common sites of immune surveillance by IST TRM cells that are located at the most vulnerable sites within the lung parenchyma.
DISCUSSION
At the internal barriers, the mucosal immune response confers the first line of defense against invading pathogens. Here, we report a distinct protective CD8 + TRM cell that is elicited by IN protein antigen plus adjuvant vaccination and localized to the lungs interstitium, an anatomical site intimately connected to the respiratory mucosa. Sublethal respiratory infections induce bronchus-associated lymphoid tissue that serves as a site for naive CD8 + T cell priming and a niche for TRM cell maintenance (Halle et al., 2009) . Accordingly, IN infection with live influenza virus elicited a robust TRM cell response that localized mostly around the large airways and blood vessels of the lungs (Wu et al., 2014) . Other studies have suggested a protective role for CXCR3 HI memory CD8 + T cells also induced by viral infection but located within the airway lumen (McMaster et al., 2015; Sl€ utter et al., 2013) . Our findings extend the types of protective TRM cells that patrol the lungs. Thus, in our IN protein antigen plus aGC adjuvant vaccination model, we identified a major CXCR3 LO IST TRM cell subset that localizes to the most vulnerable sites of infection-the alveolar and bronchiolar walls. Efficient CD8 + T cell-mediated tissue surveillance depends on high responder density (Halle et al., 2016; Steinert et al., 2015) . Accordingly, upon IN vaccination, IST TRM cells were elicited at physiologically relevant numbers and accounted for most of the lung TRM cells, suggesting these TRM cells are key initial responders to infection. Nonetheless, at the late stages of infection, we do not discount the possibility that IST TRM cells may replenish AW TRM cells, which together with systemic effector memory CD8 + T cells may substantially contribute to the resolution of infection. The mechanism by which CXCR3 LO IST TRM cells are recruited and preferentially retained in the lung interstitium upon vaccination remains unclear. In this regard, our preliminary transcriptome analysis of naive lung CD8 + T cells and purified IST TRM cells revealed many differentially expressed genes that could be associated with trafficking and/or residence in non-lymphoid tissues, including CCR7, Itgae, Cxcr6, Cxcr3, Klrg1, Klf2, and S1pr1 (P.G. and S.J., unpublished data) . The role of these genes in IST TRM cell recruitment, retention, and function awaits further study.
Devising vaccination strategies to elicit TRM cells in barrier tissues by immunization through an accessible tissue, such as skin, is an important goal for human vaccine design (Park and Kupper, 2015) . In this regard, it is noteworthy that vaccination with VACV or replication-deficient modified vaccinia virus Ankara by skin scarification elicited memory CD8 + T cells that protected mice from lethal respiratory infection, although inactivated viruses failed to do so (Liu et al., 2010) . Local immunization with CD8 + T cell-targeted epitope plus adjuvant could be a promising alternative to distal vaccination approach that uses virus vectors. Future studies will determine if vaccination by skin scarification with subunit vaccine formulation have the potential to elicit protective TRM cells that also localize to distal barrier tissues. We hope our findings will have implications for the design of safe and effective CD8 + T cell-targeted vaccines against respiratory infections.
EXPERIMENTAL PROCEDURES
Mice, Viruses, and Antigens B6-K 0 D 0 ;B*07;02 tg (B7 tg ) transgenic mice have been described elsewhere (Alexander et al., 2003) . Mouse breeding, maintenance, and experimentation complied with institutional animal care and use committee (IACUC) regulations.
The Western Reserve strain of VACV and VACV-GFP (a gift from J.W. Yewdell) were grown in and titrated with BSC-40 cells.
The design of recombinant L4R-derived antigen has been described elsewhere (Gilchuk et al., 2013) . L4R-b8r DNA was generated by substituting the sequence that encodes FPRSMLSIF (L4R 37-45 ) in L4R 33-249 DNA with a sequence that encodes FPKNDFVSF (B8R 70-78 ). Recombinant antigens were purified to high purity as described previously (Gilchuk et al., 2013) .
Vaccination, Infections, and Burden
Ketamine-xylazine-anesthetized, 6-to 8-week-old mice were inoculated intranasally or intraperitoneally twice with 50 mg antigenic protein formulated with 1 mg aGC (Funakoshi) in 100 ml PBS. To challenge, anesthetized mice were inoculated with 10 5 PFU VACV in 50 ml PBS. Mice were monitored daily for morbidity, and those losing over 30% of initial body weight were euthanized per IACUC regulations.
Lungs from individual mice were washed with PBS, homogenized, and subjected to one freeze/thaw cycle, and serial 10-fold dilutions were plated on confluent BSC-40 cells. Plaques were visualized by crystal violet staining.
IV Staining and Flow Cytometry
IV staining was performed with fluorescently labeled aCD45 Ab as described previously (Anderson et al., 2014) but modified to precisely discriminate MV, AW, and IST CD8 + T cells. After IV staining, lungs were perfused, which removes cells from the vasculature and airway lumen while retaining MV and IST CD8 + T cells within the lung parenchyma. To account for BAL CD8 + T cells, the backflow from the airways, typically generated upon perfusion, was quantitatively recovered as detailed in the Supplemental Experimental Procedures.
(C) Number of Tet + CD8 + T cells in spleen, blood, and lungs of mice vaccinated and challenged as in (B) was assessed at the indicated times (n = 3-4 mice/group, mean ± SEM). (D) Intranasally vaccinated mice were challenged with VACV or mock-inoculated with PBS (n = 4-5 mice/group). 36 hr p.i., Tet + MV CD8 + T cells and IST TRM cells were assessed for CD69 induction from pooled lungs in each group. See also Figure S5 . In Vivo CD8 + T Cell Proliferation Mice were injected with 1 mg EdU (Life Technologies) IP 24 hr before analysis. After IV staining, lung cells were labeled with viability dye to discriminate dead cells, followed by staining with tetramer and Abs. Cells were stained with Click-iT Plus EdU Alexa488 (Life Technologies) according to the manufacturer's protocol.
Confocal Microscopy and SPIM
For imaging of VACV-GFP, 10 mm fresh-frozen lung sections were stained with aGFP-Alexa Fluor 488-conjugated Ab and mouse rodoplanin Ab followed by secondary Alexa Fluor 647-conjugated Ab. For imaging of CD8 + T cells, lungs were harvested after IV staining with aCD45-BV421 Ab and fixed with 4% paraformaldehyde (PFA). Frozen 10 mm sections were stained with aCD8 + -PE Ab and AF488-labeled tomato lectin (Vector Laboratories). Confocal microscopy was performed using an AxioObserverZ.1 inverted microscope (Zeiss) equipped with a 203 1.0 numerical aperture (NA) objective; 405-nm, 488-nm, and 561-nm laser lines; and dual sCMOS cameras. Image analysis was performed with Imaris software (Bitplane Scientific). For imaging of B8R-specific CD8 + T cells in the lungs, mice were intravenously (i.v.) injected with AF488-labeled tomato lectin and aCD45-BV421 Ab, which visualizes vasculature and vascular leukocytes, respectively. Fresh, 1-mm-thick sections were cut with tissue slicer followed by overnight incubation with B8R tetramer-PE. Washed tissues were mounted in 1% agarose and analyzed using the LightsheetZ.1 platform (Zeiss) equipped with a CSU-22 spinning disc (Yokagawa), 473-nm and 660-nm laser lines, a 20À 0.75 NA Plan-Apo objective, and an Evolve EMCCD camera (Photometrics). Images were analyzed using Slidebook software (Intelligent Imaging Innovations).
Statistics
Descriptive statistics (mean ± SEM or mean ± SD) are provided for continuous variables as noted. The Wilcoxon rank-sum test or two-sample t test was applied to two-group comparisons or the post hoc group comparisons in ANOVA; all tests were two tailed and unpaired (*p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant). Statistical analyses were performed using the open source R software (version 2.15). (B) Confocal image of CD8 + IV aCD45 Ab + (MV, magenta arrow), and CD8 + aCD45 Ab À (IST; red arrow) T cells in the lung parenchyma. Lungs were harvested on day 7 after IN VACV challenge of IN prime boosted mice after IV staining with aCD45 Ab. Fixed 10-mm lung sections were stained for CD8 + T cells. Vascular endothelium is gray, vascular leucocytes are blue, and CD8 + and IV aCD45 Ab + T cells are magenta. (C) Volumetric image of Tet + IV aCD45 Ab + (MV, magenta arrow) and Tet + IV aCD45 Ab À (IST, red arrow) B8R-specific CD8 + T cells in the lung alveoli. Perfused lungs were harvested on day 14 after IN boost with L4R-b8r (left) or day 7 after IN VACV challenge (right) of IN prime boosted mice. IV staining with fluorescently labeled tomato lectin and aCD45 Ab visualizes alveolar capillary beds and vascular leucocytes, respectively; in situ tetramer staining visualizes B8R-specific CD8 + T cells. Vascular endothelium is green, vascular leucocytes are blue, and Tet + and aCD45 Ab + CD8 + T cells are magenta; CB, capillary beads. Data are representative of two or three imaging areas of three or four sections per lung of two mice from two independent experiments per condition. Scale bar sizes are as indicated in each image.
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